Ascletis Eyes Launch Of China’s First Oral HCV Drug, Possible IPO

Already well-funded Chinese venture Ascletis has completed a large Series B to support the commercialization of effective new oral HCV drugs and progress its pipeline, and has not ruled out the possibility of going public in an IPO.

SC1609_HEP-C_1200x675

Ascletis Inc., a Chinese biotech specializing in liver disease treatments with a focus on hepatitis C, has completed a major $100m Series B financing, following a first round $55m fundraising in the second half of 2015.

The second round was led by C-Bridge Capital, joined by a number of new investors including QianHai Equity Investment FOF,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip